Eli Lilly and Company (Lilly) is acquiring Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program, STX-478, for an undisclosed amount. The acquisition aims to expand Lilly’s oncology pipeline with a potentially best-in-class, mutant-selective PI3Kα inhibitor.
STX-478 has shown promise in addressing 30-40% of people with hormone-positive breast cancer. The treatment selectively targets the pathway in cancerous cells but not healthy ones, which could lead to better disease control and improved tolerability.
“This approach could potentially offer deeper pathway inhibition, as well as improved tolerability,” said [name] from Lilly. “PI3Kα mutations occur in a meaningful proportion of hormone-positive breast cancers, and there is significant unmet need for new treatment options that effectively and safely target this pathway.”
The transaction is subject to customary closing conditions and will be reflected in Lilly’s financial results and guidance. Citi is acting as exclusive financial advisor for the deal.
Scorpion Therapeutics, a clinical-stage precision oncology company, has built proprietary capabilities leveraging advanced technologies across cancer biology, medicinal chemistry, and data sciences. The acquisition marks another significant advancement by Lilly in tackling difficult-to-treat cancers.
As part of its mission to make life better for people around the world, Lilly is committed to delivering innovative clinical trials and ensuring access to affordable medicines.
Source: https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka